Keytruda SC: Big Win or Overhyped?Keytruda’s SC version is a huge step forward—faster for patients and clinics. But will it hit margins for infusion centers? Oncology still dominates, but MRK’s reliance on Keytruda is risky long-term. Thoughts? Also, I’m tracking BOLT—it’s buzzing as a potential big mover.